<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01889004</url>
  </required_header>
  <id_info>
    <org_study_id>LOC-2013</org_study_id>
    <secondary_id>266467</secondary_id>
    <secondary_id>2013-001496-21</secondary_id>
    <secondary_id>KLnro 72/2013</secondary_id>
    <nct_id>NCT01889004</nct_id>
  </id_info>
  <brief_title>The Neural Mechanisms of Anesthesia and Human Consciousness</brief_title>
  <acronym>LOC-2013</acronym>
  <official_title>The Neural Mechanisms of Anesthesia and Human Consciousness (LOC-2013)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital District of Southwestern Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The explanation of consciousness poses one of the greatest challenges to science and&#xD;
      philosophy in the 21st century. It remains unclear what consciousness is and how it emerges&#xD;
      from brain activity. By studying anesthesia and sleep, the investigators aim to reveal what&#xD;
      happens in the brain when consciousness is lost and when it returns. During the study, a&#xD;
      series of Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI) and&#xD;
      electroencephalography (EEG) studies will be carried out on healthy male subjects to reveal&#xD;
      the neural correlates of consciousness. Consciousness of the subjects will be manipulated&#xD;
      with normal sleep and anesthetic agents dexmedetomidine and propofol.&#xD;
&#xD;
      First, various neurophysiological tools to separate consciousness, connectedness and&#xD;
      responsiveness during normal sleep will be tested. The most suitable methods and subjects&#xD;
      will be selected and then tested during anesthetic-induced sedation and loss of&#xD;
      responsiveness (LOR). The anesthetics (dexmedetomidine or propofol) will be administered as&#xD;
      target-controlled infusions (TCI) with step-wise concentration-increments until LOR is&#xD;
      detected. Then, TCIs are repeated in the same subjects but adjusted according to the&#xD;
      individual drug target concentrations sufficient for LOR, and a series of PET perfusion&#xD;
      imaging measurements will be performed to obtain the brain activity information in various&#xD;
      states of consciousness. The same subjects will then be imaged with PET for brain activity&#xD;
      after sleep deprivation (awake), during various sleep stages and immediately after awakening.&#xD;
      Finally, ten dexmedetomidine subjects will be given the drug once more, and functional MRI&#xD;
      (fMRI) data will be collected at various states of consciousness before and during verbal and&#xD;
      nonverbal vocalizations. EEG will be continuously collected in all sessions. The depth of&#xD;
      anesthesia will be measured using quantitative EEG and bispectral index (BIS) monitoring.&#xD;
&#xD;
      The results may lead to the discovery of new and better objective indicators of the depth of&#xD;
      anesthesia and consciousness, and new insights into the understanding of neural mechanisms&#xD;
      behind drug-induced loss of consciousness and ultimately the mechanisms of action of&#xD;
      (general) anesthetics as well as consciousness itself.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      (not needed)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional cerebral blood flow</measure>
    <time_frame>Several measurements during two separate days within 2 months</time_frame>
    <description>Altogether 14 PET scans during two separate study days. Cerebral blood flow changes will be used as surrogates for changes in regional brain activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EEG</measure>
    <time_frame>Continuous data collection during five separate days within 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional magnetic resonance imaging (fMRI)</measure>
    <time_frame>Several measurements during one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event related potentials</measure>
    <time_frame>Several time points during five separate days within 2 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug concentration in plasma</measure>
    <time_frame>Several times points during two or three separate days within 2 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Consciousness, Level Altered</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous dexmedetomidine using target controlled infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous propofol using target controlled infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Escalating concentrations until loss of responsiveness</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Dexdor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Escalating concentrations until loss of responsiveness</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Propofol-Lipuro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age 20-30 years&#xD;
&#xD;
          -  Good general health i.e. American Society of Anesthesiologists (ASA) physical status I&#xD;
&#xD;
          -  Fluent in Finnish language&#xD;
&#xD;
          -  Right handedness&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Good sleep quality&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic medication&#xD;
&#xD;
          -  History of alcohol and/or drug abuse&#xD;
&#xD;
          -  Strong susceptibility for allergic reactions&#xD;
&#xD;
          -  Serious nausea in connection with previous anesthesia&#xD;
&#xD;
          -  Strong susceptibility for nausea&#xD;
&#xD;
          -  Any use of drugs or alcohol during the 48 hours preceding anesthesia&#xD;
&#xD;
          -  Use of caffeine products 10-12 hours prior the study, 24 hours before sleep studies&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Clinically significant previous cardiac arrhythmia / cardiac conduction impairment&#xD;
&#xD;
          -  Clinically significant abnormality in prestudy laboratory tests&#xD;
&#xD;
          -  Positive result in the drug screening test&#xD;
&#xD;
          -  Blood donation within 90 days prior to the study&#xD;
&#xD;
          -  Participation in any medical study with an experimental drug or device during the&#xD;
             preceding 60 days&#xD;
&#xD;
          -  The study subject has undergone a prior PET or SPECT study&#xD;
&#xD;
          -  Any contraindication to magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  Hearing impairment&#xD;
&#xD;
          -  Detected unsuitability based on initial electrophysiological measurements&#xD;
&#xD;
          -  Detected unsuitability based on MRI scanning results&#xD;
&#xD;
          -  Sleep disorder or severe sleep problem&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Scheinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku PET Centre</name>
      <address>
        <city>Turku</city>
        <zip>FI-20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.turkupetcentre.fi/index.php?option=com_content&amp;view=article&amp;id=268&amp;Itemid=27</url>
    <description>Research Group Home Page</description>
  </link>
  <reference>
    <citation>Långsjö JW, Alkire MT, Kaskinoro K, Hayama H, Maksimow A, Kaisti KK, Aalto S, Aantaa R, Jääskeläinen SK, Revonsuo A, Scheinin H. Returning from oblivion: imaging the neural core of consciousness. J Neurosci. 2012 Apr 4;32(14):4935-43. doi: 10.1523/JNEUROSCI.4962-11.2012.</citation>
    <PMID>22492049</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>June 23, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <last_update_submitted>January 8, 2016</last_update_submitted>
  <last_update_submitted_qc>January 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turku</investigator_affiliation>
    <investigator_full_name>Harry Scheinin</investigator_full_name>
    <investigator_title>Adjunct Professor</investigator_title>
  </responsible_party>
  <keyword>Cerebral blood flow</keyword>
  <keyword>Consciousness</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>EEG</keyword>
  <keyword>Event related potentials</keyword>
  <keyword>Functional magnetic resonance imaging</keyword>
  <keyword>General anesthesia</keyword>
  <keyword>Positron emission tomography</keyword>
  <keyword>Propofol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Consciousness Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

